日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma

度伐利尤单抗单药治疗以及与曲美利木单抗或贝伐珠单抗联合治疗不可切除肝细胞癌的T细胞受体和免疫基因表达药效学研究

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-25-1592
Kelley, Robin K; Lee, Young; Conway, James; Kurland, John F; McCoon, Patricia
肿瘤
T细胞
肿瘤免疫
信号转导
T细胞
细胞生物学
免疫/内分泌
发表日期：2026
文献求助 收藏

Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes

复发/转移性头颈部鳞状细胞癌的突变图谱及其与免疫检查点抑制剂疗效的关系

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-2198
McCoon, Patricia; Wang, Ying; Lai, Zhongwu; Zhang, Qu; Li, Weimin; Wildsmith, Sophie; Morsli, Nassim; Raja, Rajiv; Holoweckyj, Nicholas; Walker, Jill; de Los Reyes, Melissa; Mesía, Ricard; Licitra, Lisa; Ferris, Robert L; Fayette, Jérôme; Zandberg, Dan P; Siu, Lillian L; Haddad, Robert
Checkpoint
肿瘤
肿瘤免疫
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者接受曲美利单抗单药治疗或联合度伐利尤单抗治疗的暴露-反应分析

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-1983
Song, Xuyang; Kelley, Robin Kate; Khan, Anis A; Standifer, Nathan; Zhou, Diansong; Lim, KyoungSoo; Krishna, Rajesh; Liu, Lu; Wang, Kun; McCoon, Patricia; Negro, Alejandra; He, Philip; Gibbs, Megan; Kurland, John F; Abou-Alfa, Ghassan K
细胞生物学
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

STAT3 反义寡核苷酸 AZD9150 在部分接受过大量预处理的淋巴瘤患者中的疗效：一项 1b 期试验的结果

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1186/s40425-018-0436-5
Reilley, Matthew J; McCoon, Patricia; Cook, Carl; Lyne, Paul; Kurzrock, Razelle; Kim, Youngsoo; Woessner, Richard; Younes, Anas; Nemunaitis, John; Fowler, Nathan; Curran, Michael; Liu, Qinying; Zhou, Tianyuan; Schmidt, Joanna; Jo, Minji; Lee, Samantha J; Yamashita, Mason; Hughes, Steven G; Fayad, Luis; Piha-Paul, Sarina; Nadella, Murali V P; Xiao, Xiaokun; Hsu, Jeff; Revenko, Alexey; Monia, Brett P; MacLeod, A Robert; Hong, David S
JAK/STAT
STAT3
淋巴瘤
发表日期：2018
文献求助 收藏

A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.

一项针对骨髓纤维化患者的 JAK2 抑制剂 AZD1480 的 I 期、开放标签、多中心研究

期刊:Leukemia Research
影响因子:2.2
doi:10.1016/j.leukres.2014.11.018
Verstovsek Srdan, Hoffman Ronald, Mascarenhas John, Soria Jean-Charles, Bahleda Ratislav, McCoon Patricia, Tang Weifeng, Cortes Jorge, Kantarjian Hagop, Ribrag Vincent
骨科研究
发表日期：2015
文献求助 收藏

AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors

AZD1480：一种新型JAK2抑制剂在实体瘤中的I期研究

期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2013-0198
Plimack, Elizabeth R; Lorusso, Patricia M; McCoon, Patricia; Tang, Weifeng; Krebs, Annetta D; Curt, Gregory; Eckhardt, S Gail
JAK/STAT
JAK2
发表日期：2013
文献求助 收藏